Introduction
============

As the most commonly occurring urological neoplasms, renal cell carcinomas (RCCs) are almost always detected at middle or advanced stages. Even among localized RCCs that are usually defined as early-stage disease, 20-30% of cases metastasize within 1-2 years following surgery ([@b1-ijo-54-01-0348]). Nephrectomy alone is ineffective as a treatment, and systemic therapy is therefore imperative for these advanced and metastatic RCCs. In-depth investigation of the von Hippel-Lindau (VHL)/hypoxia-inducible factor (HIF) hypoxia-response pathway in RCC has led to significant progress in identifying potential molecular drug targets ([@b2-ijo-54-01-0348]). For example, patients with advanced RCC are known to benefit much more from sunitinib treatment compared with interferon-α therapy in terms of survival and disease control ([@b3-ijo-54-01-0348]). Although targeted therapy has now become the standard treatment for advanced RCC, there are clear limitations to this practice, particularly its low disease control objective response rate. In addition, the mechanisms regulating RCC growth remain unclear. Consequently, there is an urgent need to investigate the mechanisms underlying tumor growth and to identify novel treatment targets.

Approximately 70-80% of RCC cases involve clear cell RCC (ccRCC) ([@b4-ijo-54-01-0348]). Mutations or heterozygous deletions of the tumor suppressor gene, *VHL*, are known to occur in the majority of ccRCCs, leading to reduced expression of VHL protein (pVHL). pVHL is able to specifically bind to HIF and induce its ubiquitination under physiological conditions, and also under hypoxic conditions; low expression levels of *VHL* can also lead to HIF accumulation ([@b2-ijo-54-01-0348],[@b5-ijo-54-01-0348]). HIF is a nuclear transcription factor with a crucial regulatory function in activation of downstream hypoxia-responsive genes via promoter regions containing hypoxic response elements (HREs). Hence, HIF accumulation activates downstream genes, including vascular endothelial growth factor (*VEGF*), transforming growth factor-α and platelet-derived growth factor, which have important roles in tumor growth and progression ([@b2-ijo-54-01-0348],[@b6-ijo-54-01-0348]).

Bcl-2/adenovirus E1B 19 kDa interacting protein 3 (BNIP3) is a mitochondrial proapoptotic protein, and an important apoptotic regulator that belongs to the B-cell lymphoma 2 (Bcl-2) protein family ([@b7-ijo-54-01-0348]). As the only members of the Bcl-2 family with promoters containing HREs, BNIP3 and BNIP3-like protein (BNIP3L) may be activated by HIF under hypoxic conditions, and subsequently contribute to hypoxia-induced cell death via mechanisms including apoptosis, necrosis and autophagy ([@b8-ijo-54-01-0348]).

The majority of RCCs are solid tumors in which hypoxic-ischemic areas inevitably develop ([@b9-ijo-54-01-0348]-[@b12-ijo-54-01-0348]), potentially leading to HIF accumulation. In addition, as *VHL* inactivation occurs in the majority of ccRCCs, even without hypoxic stimulation, HIF may still accumulate abnormally. As a gene downstream of HIF, *BNIP3* was originally anticipated to be activated in RCC; however, a recent study demonstrated low levels of *BNIP3* expression in ccRCC, inconsistent with the high levels of HIF observed in these cancers, suggesting that a different mechanism may inhibit the expression of *BNIP3* in this context ([@b13-ijo-54-01-0348]).

Only a limited number of studies have been performed to assess the role of BNIP3 in RCC, and the mechanisms underlying its downregulation in these tumors have yet to be elucidated. In the present study, the expression of *BNIP3* in RCC tissue samples and cell lines was investigated. The methylation and histone deacetylation status of *BNIP3* in RCC was also examined, and the levels of cell proliferation and apoptosis following treatment with methylation or histone deacetylase inhibitors were investigated in order to clarify the function of BNIP3 in RCC, and to investigate its potential as a novel treatment target for RCC.

Materials and methods
=====================

Tissue samples and clinical data
--------------------------------

Samples from 30 patients, diagnosed pathologically with ccRCC between September 2012 and March 2013, and adjacent non-tumor samples, were provided by the Department of Urology of West China Hospital (Chengdu, China). Samples were used according to ethical guidelines and procedures approved by the West China Hospital of Sichuan University Biomedical Research Ethics Committee. After examination by a pathologist, tissue samples were preserved immediately in liquid nitrogen. The present study comprised 19 males and 11 females, aged 47-71 years of age (with 8 cases \>65 years of age); all patients were untreated prior to surgery. According to the staging system of the American Joint Committee on Cancer, 5, 14, 7, and 4 tumors were stage I, II, III, and IV, respectively.

Cell lines and general reagents
-------------------------------

The human ccRCC cell line, 786-O, the human RCC cell lines, ACHN, A498, and GRC-1, the normal human renal tubular epithelial cell line, HK-2, the human prostate cancer cell lines, PC3 and Du145, and the human colorectal cancer cell line, SW480, were obtained from the Laboratory of Pathology, West China Medical School, Sichuan University (Chengdu, China). Following cell dissociation and propagation, the 786-O, A498, ACHN, and GRC-1-1 cell lines were cultured (37°C) and grown in Roswell Park Memorial Institute (RPMI) medium using 1640 complete medium (Gibco^®^; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The GRC-1 RCC line was established at the Institute of Urology, Peking University (Beijing, China), was first reported by Ding *et al* ([@b14-ijo-54-01-0348]), and has been subsequently used in numerous studies ([@b15-ijo-54-01-0348],[@b16-ijo-54-01-0348]). PC3 and Du145 cells were cultured (37°C) in Dulbecco's modified Eagle's medium (DMEM) complete medium (Gibco^®^; Thermo Fisher Scientific, Inc.), whereas HK-2 cells were cultured (37°C) in F-12 Complete™ medium (Gibco^®^; Thermo Fisher Scientific, Inc.) in microcentrifuge tubes (Eppendorf, Stevenage, UK) in a humidified incubator in an atmosphere of 5% CO~2~ and 95% air.

Primer synthesis
----------------

Mature mRNA sequences were acquired from the GenBank sequence database (<http://www.ncbi.nlm.nih.gov/genbank>). Polymerase chain reaction (PCR) primers for tissue samples and culture cells were subsequently designed using Primer5 software. The primers for methylation-specific PCR of BNIP3 were identical with those used by Okami *et al* ([@b17-ijo-54-01-0348]) and Bacon *et al* ([@b18-ijo-54-01-0348]). The primers used in chromatin immunoprecipitation (ChIP) assays were designed by Shanghai Invitrogen Biotechnology Co., Ltd. (a subsidiary of Life Technologies Corporation; Shanghai, China), with the forward primer running from position 131,982,902 to position 131,982,882 of the BNIP3 template, and the reverse primer running from position 131,982,354 to position 131,982,373. All primers were synthesized by Shanghai Invitrogen Biotechnology Co., Ltd.

Reverse transcription (RT)-PCR
------------------------------

Total RNA was extracted from preserved tissue samples or cultured cells using RNAiso Plus reagent (Takara Biotechnology Co., Ltd., Dalian, China) or TRIzol reagent (Thermo Fisher Scientific, Inc.). Purified RNA was then quantified and assessed for purity using ultraviolet (UV) spectrophotometry. RT was performed with reaction mixtures (made up to a total volume of 20 *µ*l) as described in [Table I](#tI-ijo-54-01-0348){ref-type="table"}. The PCR primers used for the detection of *BNIP3* were as follows: Forward, 5′-CAGGGCTCCTGG GTAGAACT-3′ and reverse, 5′-CTACTCCGTCCAGACTCATGC-3′ (131 bp). PCR reactions were performed according to the protocol described in [Table II](#tII-ijo-54-01-0348){ref-type="table"}. PCR products were loaded onto 2% agarose gels and visualized with ethidium bromide under UV light. As a control for cDNA synthesis, RT-PCR was also performed using primers specific for the *GAPDH* gene.

RT-quantitative PCR (RT-qPCR)
-----------------------------

RT-qPCR was performed using a PTC-200 Peltier Thermal Cycler instrument (MJ Research, Ramsey, MN, USA) according to the manufacturer's protocol described in [Table III](#tIII-ijo-54-01-0348){ref-type="table"}. The sequences of the PCR primers used for detecting *BNIP3* were as follows: *VHL*, forward primer, 5′-GGAGCCTAGTCAAGCCTGAGA-3′; reverse, 5′-CATCCGTTGATGTGCAATGCG-3′ (134 bp); HIF-1α, forward primer, 5′-ATCCATGTGACCATGAGGAAATG-3′; reverse, 5′-TCGGCTAGTTAGGGTACACTTC-3′ (125 bp); *VEGF*, forward primer, 5′-AGGGCAGAATCATCACGAAGT-3′; reverse, 5′-AGGGTCTCGATTGGATGGCA-3′ (75 bp); GAPDH, forward primer, 5′-GTCTTCACCACCATGGAGAA-3′; reverse, 5′-ATCCACAGTCTTCTGGGTGG-3′ (268 bp). The GAPDH gene was used as a positive control. The PCR conditions were as follows: One cycle of denaturation at 95°C for 2 min, followed by 39 cycles of 95°C for 20 sec, 60°C for 30 sec, and 72°C for 30 sec. The copy number of target genes (relative to *GAPDH*) from the tissue samples was determined using the 2^−ΔΔCq^ method ([@b19-ijo-54-01-0348]), with ΔΔCq=ΔCq~tumor\ tissues(T)~-ΔCq~adjacent\ non-tumor\ tissues(N)~=(Cq~T-target~-Cq~T-~*~GAPDH~*)-(Cq~N-target~-Cq~N-~*~GAPDH~*), whereas the copy number for cultured cells was determined by the ΔCq method, with ΔCq=Cq*~GAPD~*~H~-Cq*~gene~*.

Western blotting
----------------

Total cell protein was collected from cells following lysis in buffer (Roche Diagnostics GmbH, Mannheim, Germany) containing leupeptin, pepstatin A, aprotinin and phenylmethanesulfonyl fluoride (PMSF). The protein concentration was measured using the bicinchoninic acid (BCA) protein assay reagent kit (Beyotime Institute of Biotechnology, Haimen, China). After mixing with SDS loading buffer (Calbiochem; now a subsidiary of EMD/Merck Millipore, Billerica, MA, USA) and boiling for 5 min, the protein samples were separated by SDS/PAGE gels (12%) and transferred on to a polyvinylidene difluoride (PVDF) membrane (GE Healthcare Life Sciences, Little Chalfont, UK). Membranes were subsequently blocked with 15% fat-free milk powder (for BNIP3) or 5% fat-free milk powder (for VHL, HIF-1α, VEGF and GAPDH), and separated in Tris-buffered saline containing 0.1% Tween-20 (TBST) buffer for 90 min at room temperature. Corresponding membranes were then incubated with primary antibodies against BNIP3 (cat. no. B7931, 1:3,000; Sigma-Aldrich; now a brand of Merck, KGaA, Darmstadt, Germany), VHL (cat. no. 68547, 1:1,000; CST Biological Reagents Co., Ltd., Shanghai, China), HIF-1α (cat. no. 610959, 1:2,000; BD Biosciences, San Jose, CA, USA), VEGF (cat. no. BA0407, 1:100; Boster Biological Technology, Pleasanton, CA, USA), and GAPDH (cat. no. KC-5G4, 1:10,000; Kangchen BioTech Co., Ltd., Shanghai, China) at 4°C overnight. After washing in TBST buffer, the membranes were subsequently incubated with horseradish peroxidase (HRP)-conjugated goat anti-mouse or rabbit IgG secondary antibodies (cat. nos. 31430 for mouse and 31460 for rabbit, respectively; 1:5,000; Zymed^®^; Thermo Fisher Scientific, Inc.) at room temperature for 1 h. After further TBST washing, the antigen-antibody reaction was visualized using the enhanced chemiluminescence (ECL) assay (Roche Diagnostics GmbH), and the blots were analyzed using a DP70 digital camera (Olympus Corporation, Tokyo, Japan). The intensity (gray value) of each protein sample was calculated and normalized to the internal control, GAPDH.

Genomic DNA isolation, methylation modification, and methylation-specific (MS)-PCR
----------------------------------------------------------------------------------

Genomic DNA was isolated from tissue samples and cultured cells using a Promega DNA purification kit (Promega Corporation, Madison, WI, USA), in accordance with the manufacturer's protocol. After the purity and concentration of DNA was quantified and assessed, methylated residues were modified using a ZYMO DNA Methylation-Gold kit (Zymo Research Corp., Irvine, CA, USA) to differentiate methylated CpGs from unmethylated CpGs. Using this treatment, unmethylated cytosines were converted into uracil, whereas methylated cytosine remains as cytosine. Subsequently, MS-PCR was performed using the reaction mixtures described in [Table II](#tII-ijo-54-01-0348){ref-type="table"}. The PCR conditions were as follows: One cycle of denaturation at 95°C for 5 min, followed by 35 cycles of 95°C for 30 sec, 64 or 58°C (methylated or unmethylated) for 50 sec, and 72°C for 30 sec. Primer sequences for the unmethylated reaction were as follows: Forward, 5′-TAGGATTTGTTTTGTGTATG-3′, and reverse, 5′-ACCACATCACCCATTAACCACA-3′ (94 bp), whereas for the methylated reaction, the following primers were used: Forward, 5′-TAGGATTCGTTTCGCGTACG-3′, and reverse, 5′-ACCGCGTCGCCCATTAACCGCG-3′ (94 bp).

Assessment of cell proliferation following treatment with 5-aza-cytidine (5-aza-C) or TSA
-----------------------------------------------------------------------------------------

Cells collected from cell culture flasks were grown on 96-well plates (Corning Incorporated, Corning, NY, USA) at a concentration of 5×10^3^ cells per well, and then incubated with in atmosphere of 5% CO~2~ and 95% air. After 24 h of incubation, the culture medium was substituted with medium containing 2% fetal calf serum and 5 *µ*M 5-aza-C (Merck, KGaA) or 1.5 *µ*M of the histone deacetylase inhibitor (HDACI), TSA (Merck, KGaA), which was renewed every 12 h for 72 h. Following treatment, 10 *µ*l cholecystokinin octapeptide (CCK-8) (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was added to each tube, followed by incubation for 4 h. Finally, in order to determine the levels of cell proliferation, absorbance at 450 nm was measured using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

Evaluation of proliferation and apoptosis following treatment with different concentrations of TSA
--------------------------------------------------------------------------------------------------

Cultured cells (786-O, ACHN, and A498) used to evaluate proliferation were grown on 96-well plates at a concentration of 3×10^3^ cells per well, whereas cells for apoptotic evaluation were grown on 6-well plates (Corning Incorporated) at a concentration of 1.2×10^6^ cells per well. Subsequently, cells were incubated in an atmosphere of 5% CO~2~ and 95% air for 24 h prior to renewing the media containing 0.5, 1.0, or 2.0 *µ*mol/l TSA, as appropriate. Cells treated with medium without TSA were used as a negative control, whereas medium without the cells was used as a blank control. The cell medium was renewed every 24 h for all groups. The proliferation of cells was evaluated at 0, 24, 48, and 72 h using CCK-8, as described above. Apoptosis was examined at 48 h using Annexin V-fluorescein isothiocyanate (FITC) (Dojindo Molecular Technologies, Inc.,) and flow cytometry (Instrument: Bio-Rad Laboratories, Inc; Software: NoveExpress™), in accordance with the manufacturer's protocol.

Evaluation of gene expression following TSA treatment
-----------------------------------------------------

Total RNA was extracted from cultured cells treated with different concentrations of TSA for 24 h as described above, with cells grown in medium without TSA being used as a negative control. RT-PCR was performed with the reaction mixtures described in [Table I](#tI-ijo-54-01-0348){ref-type="table"}, whereas PCR was performed with the reaction mixtures described in [Table IV](#tIV-ijo-54-01-0348){ref-type="table"}. The PCR conditions were as follows: One cycle of denaturation at 95°C for 1 min, followed by 35 cycles of 95°C for 10 sec, 58°C for 30 sec, and 72°C for 30 sec. PCR products were loaded onto 2% agarose gels and visualized with ethidium bromide under ultraviolet (UV) light. As a control for cDNA synthesis, RT-PCR was also performed using primers specific for the *GAPDH* gene. RT-qPCR was performed with the reaction mixtures described in [Table III](#tIII-ijo-54-01-0348){ref-type="table"}. The RT-qPCR conditions were as follows: One cycle of denaturation at 95°C for 1 min, followed by 40 cycles of 95°C for 10 sec, 60°C for 30 sec, and 72°C for 30 sec. The *BNIP3* primers for PCR were as follows: Forward, 5′-ACCAACAGGGCTTCTGAAC-3′; reverse, 5′-GAGGGTGGCCGTGCGC-3′ (204 bp). *GAPDH* was used as an internal control, and primers were as described above. Reactions without the cDNA template were used as blank controls. Western blotting for the analysis of protein expression was subsequently performed, as described above.

ChIP assay
----------

Cultured cells (786-O, ACHN, and A498) for the evaluation of *BNIP3* promoter deacetylation were grown on 100 mm cell-culture dishes (Corning Incorporated) and incubated in an atmosphere of 5% CO~2~ and 95% air for 24 h. Subsequently, the medium was renewed for medium containing 1.0 *µ*mol/l TSA. Cells treated with media without TSA were used as a negative control. Cell media was renewed every 24 h for all groups. After the cells had been treated with TSA for 48 h, commercial ChIP kits (Beyotime Institute of Biotechnology) were used to perform the ChIP assays. In brief, cells were fixed in formaldehyde (Sigma-Aldrich; now a branch of Merck, KGaA) for 10 min, quenched with glycine solution for 5 min, and washed twice with phosphate-buffered saline (PBS) supplemented with PMSF. Subsequently, the cells were harvested, centrifuged (4°C, 1,000 × g for 2 min), resuspended in SDS lysis buffer and ice-bath sonicated (50W, 6 times for eight cycles) to break up the DNA into 20-1,000 bp fragments. After centrifugation (4°C, 14,000 × g for 5 min), 500 *µ*l aliquots of the supernatant (containing DNA) were diluted to 2 ml in ChIP dilution buffer. Input samples were used as positive controls, and collected prior to the addition of Protein A+G agarose/salmon-sperm DNA, centrifugation (4°C, 1,000 × g for 1 min), and the immunoprecipitates being divided into two 1 ml samples. Anti-acetylated histone H3 polyclonal antibody (EMD/Merck Millipore) was added to the experimental group samples, whereas normal rabbit IgG antibodies were added to negative control samples. All samples were mixed with Protein A+G agarose/salmon-sperm DNA, centrifuged (4°C, 1,000 × g for 1 min), and then washed successively using Low Salt Immune Complex Wash buffer, High Salt Immune Complex Wash buffer, and LiCl Immune Complex Wash buffer once, and TE buffer twice. Bound complexes were eluted using elution buffer. DNA-protein crosslinking was reversed by incubation with 5 M NaCl for 4 h at 65°C, and input samples were diluted to 100 *µ*l and incubated under the same conditions. DNA samples were subsequently purified using a DNA purification kit (Beyotime Institute of Biotechnology), according to the manufacturer's protocol. After the DNA had been purified, PCR was performed according to the protocol described in [Table IV](#tIV-ijo-54-01-0348){ref-type="table"}. The PCR conditions were as follows: One cycle of denaturation at 95°C for 1 min, followed by 35 cycles of 95°C for 10 sec, 55°C for 30 sec, and 72°C for 30 sec. Reactions containing no DNA template were used as blank controls. Reaction products were subjected to agarose gel electrophoresis (2%), and analyzed under UV light, as described above. The *BNIP3* ChIP primers employed in these analyses were as follows: 5′-AGCGGGAAATTGAGAAAGCGA-3′ (forward) and 5′-TCCATCCTGCTAGTGGGGAA-3′ (reverse; 548 bp).

Statistical analysis
--------------------

Data associated with the tissue samples are presented as the median and the inter-quartile range (IQR). Statistically significant differences were determined using a single-sample non-parametric test, correlation analyses were determined by rank correlation, and P\<0.05 was taken to indicate a statistically significant value. Data from cultured cells are presented as the mean ± standard error (SE). Unpaired t-tests were used for determining statistically significant differences, which were defined as P\<0.05.

Results
=======

Expression levels of BNIP3 and associated genes in RCC tissue samples and cultured cells
----------------------------------------------------------------------------------------

RT-qPCR was used to examine the mRNA expression levels of *BNIP3* and associated genes. In tissue samples collected from patients with ccRCC, *BNIP3* and *VHL* expression levels were lower in tumor tissues compared with those in adjacent non-tumor tissues, with median relative transcript levels of 0.30 (IQR=0.17-0.44; P\<0.05) and 0.51 (IQR=0.34-0.69; P\<0.05), respectively (the relative expression level of each gene is shown relative to levels in adjacent non-tumor control tissue samples, which were set to 1) ([Table V](#tV-ijo-54-01-0348){ref-type="table"}). However, the mRNA expression levels of *HIF1A* and *VEGF* were higher in tumor tissues compared with adjacent non-tumor tissues, with median relative transcript levels of 12.30 (IQR=6.92-34.98; P\<0.05) and 13.14 (IQR=9.30-24.73; P\<0.05), respectively.

Statistical analysis of the gene expression data, according to the clinical characteristics of the tumors, indicated that *VHL* mRNA expression was negatively correlated with pathological tumor stage (r=−0.40; P\<0.05), whereas no significant correlations with gender, age, size of tumor, or clinical stage were detected (P\>0.05; [Table V](#tV-ijo-54-01-0348){ref-type="table"}). Furthermore, the expression of *HIF1A* was positively correlated with the pathological and clinical tumor stage (r=0.84, 0.47; P\<0.01); however, no significant correlations were observed for gender, age, or the size of tumor (P\>0.05). *VEGF* expression was negatively correlated with clinical tumor stage (r=−0.40; P\<0.05), but there were no significant correlations with gender, age, size of tumor or pathological stage (P\>0.05). There were no significant correlations between *BNIP3* mRNA expression levels and gender, age, size of tumor, or clinical or pathological stage (P\>0.05). Likewise, there were there no significant correlations among the expression levels of *BNIP3*, *VHL*, *HIF1A*, and *VEGF*.

To explore protein expression in RCC, western blots were performed, which revealed reduced levels of BNIP3 and VHL in RCC tumors compared with adjacent non-tumor tissue samples (relative expression levels, 0.56 and 0.23, respectively; P\<0.05; [Fig. 1A](#f1-ijo-54-01-0348){ref-type="fig"}). In contrast, HIF-1α and VEGF were expressed at significantly higher levels in tumor tissue samples (1.12 and 3.45, respectively; P\<0.05).

For cultured cells, RT-qPCR demonstrated that *BNIP3* expression levels were lower in all RCC cell lines investigated (786-O, ACHN, A498, and GRC-1-1; P\<0.05; [Fig. 1B](#f1-ijo-54-01-0348){ref-type="fig"}) when compared with the normal human renal tubular epithelial cell line, HK-2, with relative transcript levels of 1.5, 12, 7 and 8%, respectively. As expected, western blots of cultured cells demonstrated reduced levels of BNIP3 in the 786-O, ACHN, and A498 lines compared with the HK-2 cell line ([Fig. 1C](#f1-ijo-54-01-0348){ref-type="fig"}); these findings were consistent with the RT-qPCR results.

Methylation status of the BNIP3 gene promoter region in RCC
-----------------------------------------------------------

Our results indicated a reduced *BNIP3* expression in RCC tissues and cells, which may have been caused by methylation of its promoter region ([@b17-ijo-54-01-0348]). To determine whether the promoter region of *BNIP3* was methylated, and to explore the epigenetic regulation of this gene in RCC, MS-PCR was performed ([Fig. 2A](#f2-ijo-54-01-0348){ref-type="fig"}). The human colorectal cancer cell line, SW480, in which the *BNIP3* promoter region is methylated, was chosen as a positive control. Our analysis failed to identify evidence of any methylation in the *BNIP3* promoter region in either the HK-2 cells or the adjacent non-tumor tissues, in addition to the 786-O, ACHN, and A498 RCC cell lines and the patient ccRCC tumor samples, suggesting that reduced *BNIP3* expression in RCC is not likely to be due to methylation of the *BNIP3* promoter region.

Subsequently, tumor cells were treated with the demethylation inhibitor, 5-aza-C, and their proliferation was examined. In the presence of a methylated *BNIP3* promoter region in RCC cells, treatment with 5-aza-C would be expected to induce the upregulation of *BNIP3*, and the consequential promotion of apoptosis. The cell line 786-O, which exhibited low *BNIP3* expression, was chosen for the 5-aza-C treatment experiments. The findings of this experiment revealed that there were no significant differences in proliferation following demethylation treatment, consistent with the results of MS-PCR ([Fig. 2B](#f2-ijo-54-01-0348){ref-type="fig"}).

As previously published studies have reported that certain tumors with reduced *BNIP3* expression exhibit histone deacetylation ([@b18-ijo-54-01-0348],[@b20-ijo-54-01-0348]), RCC cells were also treated with trichostatin A (TSA), a type of histone deacetylase inhibitor (HDACI). Treatment with TSA inhibited the growth of tumor cells by 70.4% after 72 h treatment (\|A~TSA~-A~Blank~\|/A~Blank~; P\<0.05; [Fig. 2B](#f2-ijo-54-01-0348){ref-type="fig"}). This led us to hypothesize that the inhibition of deacetylation might activate *BNIP3* expression.

Treatment with an HDACI suppresses tumor proliferation and promotes apoptosis
-----------------------------------------------------------------------------

To test our hypothesis that *BNIP3* expression might be activated by inhibiting deacetylation, the proliferation levels of 786-O, A498, and ACHN cells were examined following treatment with different concentrations of TSA (0.5, 1.0, and 2.0 *µ*mol/l) ([Fig. 3A](#f3-ijo-54-01-0348){ref-type="fig"}). The absorbance values at 450 nm of TSA-treated cells were significantly lower compared with those of the controls (P\<0.05); however, no significant differences were detected among different cell lines (P\>0.05), and no concentration-dependence inhibition effects of TSA upon cell proliferation were observed.

Apoptosis was also examined in cultured cells exposed to HDACI by using Annexin V-FITC flow cytometric analysis ([Fig. 3B](#f3-ijo-54-01-0348){ref-type="fig"}). As shown in [Fig. 3B](#f3-ijo-54-01-0348){ref-type="fig"}, after TSA-treatment for 48 h, levels of early apoptotic (EA) cells were significantly increased (P\<0.05), with no significant differences noted among cultured cells or in response to different concentrations of TSA. Levels of late apoptotic (LA) and necrotic 786-O cells were significantly increased (P\<0.05). Consequently, it appears that the inhibition of deacetylation may suppress tumor growth, and promote apoptosis.

Treatment with TSA leads to the upregulation of BNIP3 expression
----------------------------------------------------------------

As our results indicated that HDACI caused RCC cell death, whether TSA treatment could activate *BNIP3* expression was subsequently investigated. Therefore, RT-qPCR on cultured cells treated with TSA at different concentrations (0.5, 1.0, and 2.0 *µ*mol/l) was performed ([Fig. 4A](#f4-ijo-54-01-0348){ref-type="fig"}). After treatment for 24 h, *BNIP3* mRNA expression markedly increased in all three RCC cell lines (786-O, A498, and ACHN; P\<0.05). In 786-O cells, expression levels for each TSA concentration (0.5, 1.0 and 2.0 *µ*mol/l) were determined to be 247, 395, and 366 times higher compared with the controls (P\<0.05), although no significant differences were observed among cells treated with each TSA concentration (P\>0.05). However, for the other two cell lines (A498 and ACHN), the increases in expression were less pronounced compared with those observed in the 786-O cell line. For the cell lines ACHN and A498, significant differences were identified between cells treated with 0.5 and 1.0, and 0.5 and 2.0 *µ*mol/l TSA (P\<0.05), although no significant differences were identified between cells treated with 1.0 and 2.0 *µ*mol/l TSA (P\>0.05).

Western blotting was also performed to explore BNIP3 protein expression following treatment with TSA ([Fig. 4B](#f4-ijo-54-01-0348){ref-type="fig"}). BNIP3 protein was hardly expressed at all in the 786-O, A498, or ACHN cells prior to treatment. However, following the addition of TSA (0.5 or 1.0 *µ*mol/l) for 48 h, BNIP3 protein expression markedly increased (P\<0.05), with the most pronounced increase observed for 786-O cells, consistent with the RT-qPCR results. Although the difference in BNIP3 expression recorded for 786-O cells treated with either 0.5 or 1.0 *µ*mol/l TSA was statistically significant (P\<0.05), this was not the case for the other two cell lines investigated (ACHN and A498 cells; P\>0.05). Taken together, the results of the RT-qPCR and western blotting experiments indicated that TSA treatment activated BNIP3 expression in RCC.

Histone deacetylation of the BNIP3 promoter region in RCC cells
---------------------------------------------------------------

As our results indicated that HDACI treatment led to an increase in BNIP3 expression and the induction of apoptosis in RCC cells, subsequently the histone deacetylation status of the *BNIP3* promoter region in RCC cells was determined, as this could have provided an explanation for the effects of TSA. ChIP assays demonstrated that histone H3 was deacetylated in the *BNIP3* promoter region in 786-O and ACHN cells, and that histone H3 became acetylated after 48 h treatment with TSA (1.0 *µ*mol/l, [Fig. 5](#f5-ijo-54-01-0348){ref-type="fig"}). However, there was no change in histone H3 acetylation in the A498 cells following treatment with TSA.

Discussion
==========

The BNIP3 protein exhibits homology with the BH3 domain of B-cell lymphoma 2 (Bcl-2) protein, and is an atypical member of the BH3-only subfamily ([@b21-ijo-54-01-0348]). The mechanisms that connect mitophagy with apoptosis are complicated, and these include synergistic, antagonistic, and stimulatory effects; BNIP3 also connects mitophagy with apoptosis, thus affecting the ultimate fate of cells ([@b22-ijo-54-01-0348]-[@b26-ijo-54-01-0348]). BNIP3 is able to induce mitochondrial autophagy in response to environmental changes to promote cell survival; however, under seriously detrimental environmental conditions, excessive mitochondrial autophagy is induced, leading to apoptosis ([@b27-ijo-54-01-0348]) ([Fig. 6](#f6-ijo-54-01-0348){ref-type="fig"}). The expression of BNIP3 in different tumors has been shown to be inconsistent, as high expression levels of BNIP3 have been reported in numerous other tumor types, including prostate cancer, spongioblastoma, endometrial carcinoma, cervical cancer, invasive breast cancer and lung cancer, to cite a few examples ([@b28-ijo-54-01-0348]). Furthermore, low levels of BNIP3 expression have been observed in pancreatic cancer, gastric carcinoma, colorectal cancer and ccRCC ([@b28-ijo-54-01-0348]). Either BNIP3 activation or silencing has been shown to promote tumor invasion, delay cell death, and subsequently lead to poor prognosis in different types of tumor ([@b14-ijo-54-01-0348],[@b29-ijo-54-01-0348]-[@b32-ijo-54-01-0348]). However, the regulatory mechanism of BNIP3 in ccRCC has yet to be elucidated.

As a hypoxia-responsive gene downstream of HIF, BNIP3 was originally considered to be overexpressed in response to HIF upregulation; however, according to a study which examined 104 RCC tumor samples and 48 adjacent non-tumor tissue samples, the lower levels of BNIP3 expression in tumor tissues was not accompanied by high expression levels of HIF-1α and VEGF in ccRCC ([@b13-ijo-54-01-0348]). The present study revealed that the expression of BNIP3 and VHL in tumor tissues was lower compared with adjacent non-tumor tissues, whereas the expression of HIF-1α and VEGF was higher in tumor tissues at the mRNA and protein levels. Furthermore, low levels of BNIP3 expression were also observed in RCC cell lines. These results suggest that the BNIP3 pathway may be blocked in a certain way, although the hypoxia/HIF-1 pathway remains intact, and HIF-1 continues to be normally activated in RCC.

As previously described, BNIP3 silencing might facilitate tumor survival. According to a study by Erkan *et al* ([@b32-ijo-54-01-0348]), the loss of BNIP3 expression contributes to chemoresistance and poor prognosis in pancreatic cancer. In another study, Okami *et al* ([@b17-ijo-54-01-0348]) described the contribution of BNIP3 silencing to the aggressive nature of pancreatic cancer. A reduced expression of BNIP3 has also been reported in cases of chemotherapy-resistant colon cancer ([@b33-ijo-54-01-0348],[@b34-ijo-54-01-0348]). In the present study, no association was identified between BNIP3 expression level and any of the pathological parameters examined in patients with RCC. This may be due to the relatively low number of samples included in this study, and additional studies featuring a larger number of samples will be required to obtained more conclusive results. In addition, VHL expression was also shown to be negatively correlated with the tumor pathological stage, whereas that of HIF-1α exhibited the opposite correlation, suggesting that the HIF-1 pathway may have a role in the progression of RCC. VEGF acts downstream of HIF-1; however, our study demonstrated a negative correlation between VEGF and clinical parameters, a finding which was not consistent with the results of previous studies ([@b13-ijo-54-01-0348],[@b35-ijo-54-01-0348]). Again, a larger sample size is required in order to confirm these findings.

Epigenetic regulation, a modulation of gene expression that does not rely on changes in the DNA sequence, can be stably inherited in proliferating cells. DNA methylation and histone deacetylation are two epigenetic mechanisms with crucial roles in tumorigenesis and tumor progression. Hypermethylation always occurs at CpG islands, which were originally defined as regions of DNA with a G+C ratio \>0.5 and an observed vs. expected frequency of CpGs, which was shown to be \>0.6 ([@b36-ijo-54-01-0348]). The majority of CpG islands are associated with promoter regions of housekeeping or tissue-specific genes ([@b37-ijo-54-01-0348]), and CpG hypermethylation contributes to the functional inactivation of genes involved in growth regulation ([@b38-ijo-54-01-0348]) and DNA repair ([@b39-ijo-54-01-0348]). The modification of histones leads to alterations in the interactions between DNA and histones, thus influencing chromatin tension and, subsequently, the regulation of transcription. Deacetylation is the most important mechanism involved in histone modification, which leads to the inhibition or silencing of genes, including tumor suppressor genes.

DNA methylation is a proven mechanism of BNIP3 downregulation in tumors. In a previous study, Murai and coworkers demonstrated that BNIP3 was methylated in 65.6% of colorectal cancer tissues, although it was not methylated in adjacent normal tissue samples ([@b15-ijo-54-01-0348],[@b40-ijo-54-01-0348]). Similarly, Cleven *et al* ([@b41-ijo-54-01-0348]) also demonstrated the occurrence of *BNIP3* methylation in 52.8% of colorectal cancer cells, and that treatment with 5-aza-C restored the expression of *BNIP3* and led to increased apoptosis and autophagy, with enhanced sensitivity to chemotherapy. In another study, Okami *et al* ([@b17-ijo-54-01-0348]) and Abe *et al* ([@b42-ijo-54-01-0348]) observed methylation of the *BNIP3* promoter in pancreatic cancer. In the current study, no methylation was detected in the *BNIP3* promoter region of either RCC tissues or cell lines. In addition, treatment with 5-aza-C did not induce any changes in RCC cell proliferation. These data suggest that the downregulation of BNIP3 in RCC is not induced by methylation, but, instead, is a consequence of histone deacetylation.

Murai *et al* ([@b20-ijo-54-01-0348]) and Bacon *et al* ([@b18-ijo-54-01-0348]) treated colorectal cancer cells with the HDACI, TSA, leading to BNIP3 upregulation; Murai *et al* ([@b40-ijo-54-01-0348]) also identified histone acetylation of the *BNIP3* promoter region. In the present study, the mRNA and protein expression levels of BNIP3 were increased following treatment of the RCC 786-O, ACHN, and A498 cell lines with TSA, and ChIP assays demonstrated histone deacetylation in the *BNIP3* promoter region of 786-O and ACHN RCC cells, with the acetylation status restored following TSA treatment. Therefore, it may be concluded that histone deacetylation is a primary cause of *BNIP3* inactivation in RCC.

However, A498 RCC cells did not exhibit histone deacetylation in the *BNIP3* promoter, and treatment with TSA led to an increase in BNIP3 expression with no changes detected in the *BNIP3* promoter. Bacon *et al* ([@b18-ijo-54-01-0348]) previously found that BNIP3 was upregulated following either 5-aza-C or TSA treatment in certain types of colorectal cancer cells, which had no initial methylation or histone deacetylation in the *BNIP3* promoter region. This observation suggests that other mechanisms, and not only histone deacetylation, are involved in the inactivation of BNIP3 in RCC.

As a HDACI, TSA is known to reverse the deacetylated status of histones ([@b43-ijo-54-01-0348]), which could possibly play a role in the mechanisms described above. The growth inhibition and apoptosis induction characteristics of TSA have also been established in several types of tumor cells ([@b44-ijo-54-01-0348]). Similarly to BNIP3, the expression of numerous other genes, including p27 ([@b45-ijo-54-01-0348]), increased following TSA treatment in RCC, which leads to the promotion of cell apoptosis. Along with the increased expression of several genes, TSA is able to activate a range of signaling pathways, including the c-Jun N-terminal kinase (JNK) signaling pathway ([@b46-ijo-54-01-0348]), to promote cell apoptosis, or it can suppress pathways, such as the Wnt/beta catenin signaling pathway ([@b47-ijo-54-01-0348]). However, the mechanisms according to which these pathways interact, both with each other and with BNIP3, have yet to be elucidated, and further studies are therefore required.

In the present study, no concentration-dependent effects for TSA treatment on cell proliferation and apoptosis were observed, possibly since the concentrations that were selected for comparison were too high, and the difference between the selected concentrations was relatively small. Additionally, no significant differences in the expression levels of *BNIP3* mRNA were observed when comparisons were made between groups treated with 1.0 or 2.0 *µ*mol/l TSA. Hence, in subsequent Western blotting experiments, the TSA 0.5 and 1.0 *µ*mol/l treatment groups were selected for comparison, and only the 1.0 *µ*mol/l TSA treatment group was selected for the ChIP assay as the largest effects were observed in this group in our initial experiments.

Since the advent of molecular-targeted drugs, significant progress has been made in terms of renal cancer treatment. Agents acting on targets in the VHL-HIF hypoxia-response gene pathway have increased the rate of disease control to almost 80%; however, according to the Response Evaluation Criteria In Solid Tumors (RECIST), targeted therapies mostly lead to stable disease, with low objective response rates ([@b48-ijo-54-01-0348]). As a gene downstream of HIF, *BNIP3* encodes a mitochondrial pro-apoptotic protein which has an important role in the biological behavior of renal carcinoma cells. Research geared towards the development of new methods for restoring BNIP3 expression and promoting its effects in causing RCC tumor cell death may provide novel options for RCC treatment; however, the demonstration of the mechanism of BNIP3 inactivation in RCC in the present study was restricted to *in vitro* experiments, and our findings require further confirmation in an animal model. In addition, as a broad-spectrum HDAC, TSA is able to induce tumor cell apoptosis in several different ways. The specific blocking and restoration of BNIP3 expression are now required to further explore the role of BNIP3 in the molecular pathogenesis of RCC.

In conclusion, in the present study low levels of expression of the pro-apoptosis gene, *BNIP3*, were demonstrated in RCC cells with VHL inactivation and HIF upregulation, and *BNIP3* promoter methylation did not contribute to *BNIP3* suppression. TSA treatment was demonstrated to restore the acetylated status of the *BNIP3* gene, increase BNIP3 expression at both the mRNA and protein levels, inhibit cell proliferation, and induce RCC cell death, thereby indicating that deacetylation of the promoter region histone appears to be a mechanism of *BNIP3* inactivation, and that BNIP3 could be a potential new target for RCC treatment.
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![BNIP3 expression in ccRCC tumor tissue samples, adjacent non-tumor tissue samples, and cell lines. (A) Relative protein expression levels of BNIP3, VHL, HIF-1α, and VEGF in tumor and adjacent non-tumor tissue samples from 30 cases of ccRCC were determined by WB using the levels of GAPDH as an internal control. Data are presented as the median and interquartile range. T, tumor tissues; N, adjacent non-tumor tissues. ^\*^P\<0.05 compared with adjacent non-tumor tissues. Representative examples are shown. (B) RT-qPCR, demonstrating that *BNIP3* mRNA expression was significantly lower in 786-O, ACHN, A498 and GRC-1-1 RCC cells (particularly 786-O cells) compared with normal renal HK-2 cells. BNIP3 mRNA expression levels were measured as percentages of that of HK-2. ^\*^P\<0.05 compared with ACHN, GRC-1-1, 786-O, A498 cells. (C) BNIP3 protein levels in 786-O, ACHN, A498, GRC-1-1, and HK-2 cells were evaluated by WB, with GAPDH as a control. A representative example is shown. WB, western blotting; VHL, Hippel Lindau; HIF-1α, hypoxia-inducible factor-1α; VEGF, vascular endothelial growth factor; ccRCC, clear cell renal cell carcinoma; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.](IJO-54-01-0348-g00){#f1-ijo-54-01-0348}

![Methylation status of the *BNIP3* promoter in RCC cells. (A) Methylation-specific PCR analysis of the colorectal cancer cell line, SW480, the normal renal cell line, HK-2, the RCC cell lines, 786-O, A498, ACHN, and GRC-1-1, and RCC tumor tissues (T) and adjacent non-tumor tissues (N) from 30 cases with RCC. The *BNIP3* promoter was methylated in SW480 cells, which was set as a positive control. No methylation was observed in the HK-2 cells or in the 30 samples of RCC adjacent non-tumor tissues; this was also the case for the 786-O, A498, ACHN, and GRC-1-1 cell lines, and 30 samples of RCC tumor tissues (two representative cases are presented here). M, methylated; UM, unmethylated. (B) 786-O cells, which showed the lowest expression levels of BNIP3 among the four RCC cell lines investigated, were cultured with or without 5-aza-C or TSA for 72 h. Cells treated with no drugs were set as a blank control. Tumor cell proliferation was examined using the Cell Counting Kit-8. No significant differences were found between the 5-aza-C group and the untreated group; however, TSA significantly inhibited RCC cell growth compared with the blank group. ^\*^P\<0.05 compared with the blank group. 5-aza-C, 5-aza-cytidine; TSA, trichostatin A; RCC, renal cell carcinoma; PCR, polymerase chain reaction.](IJO-54-01-0348-g01){#f2-ijo-54-01-0348}

![Evaluation of RCC cell proliferation and apoptosis following treatment with TSA. (A) 786-O, ACHN, and A498 cells were treated with different concentrations of TSA (0.5, 1.0, and 2.0 *µ*mol/l). Untreated cells were used as the control group (blank), and cell proliferation was evaluated using Cell Counting Kit-8 assay every 24 h for 72 h. ^\*^P\<0.05 compared with each TSA-treated group; ^a^P\<0.05 compared with TSA 0.5 and 1.0 *µ*mol/l treatment groups for 786-O after 24 h treatment; ^b^P\<0.05 compared with the TSA 1.0 *µ*mol/l treatment group for 786-O after 48 h treatment; ^c^P\<0.05 compared with the TSA 2.0 *µ*mol/l treatment group for 786-O after 72 h treatment; ^d^P\<0.05 compared with the TSA 0.5 and 1.0 *µ*mol/l treatment groups for ACHN after 72 h treatment; ^e^P\<0.05 compared with the TSA 0.5 and 2.0 *µ*mol/l treatment groups for A498 after 48 h treatment; ^f^P\<0.05 compared with the TSA 2.0 *µ*mol/l treatment group for A498 after 72 h treatment. (B) Three cells lines were treated with TSA at different concentrations, and untreated cells were used as controls (blank). Apoptosis was evaluated using Annexin V-FITC flow cytometric analysis, with concentration of cells for flow cytometry was 2×10^5^/ml. FITC-H binds to Annexin V, an increase of which indicates elevated EA, whereas PE-Texas Red H binds propidium iodide, an increase of which indicates elevated LA. Histograms show the apoptotic status of RCC cells. ^\*^P\<0.05 compared with each TSA treatment group. Representative flow cytometric scatter plots are presented under the histograms. Each quarter in the coordinate system represents a different cell status, and the proportional change in each quarter reflects the effect of TSA treatment on cells. Q2-1, cells that have sustained mechanical injury; Q2-2, late apoptotic and necrotic cells; Q2-3, normal cells; Q2-4, early apoptotic cells. EA, early apoptosis; LA, late apoptosis; RCC, renal cell carcinoma; TSA, trichostatin A; FITC, fluorescein isothiocyanate.](IJO-54-01-0348-g02){#f3-ijo-54-01-0348}

![BNIP3 expression in 786-O, A498, and ACHN cells following treatment with TSA. (A) Expression of *BNIP3* mRNA in 786-O, ACHN and A498 cells was quantified by RT-qPCR after treatment with TSA for 24 h. The untreated controls (blank) for each of the three cell lines were assigned a relative value of 1. ^\*^P\<0.05 compared with treatment groups (^a^P\<0.05 compared with TSA 1.0 and 2.0 *µ*mol/l treatment groups for ACHN cells; ^b^P\<0.05 compared with TSA 1.0 and 2.0 *µ*mol/l treatment groups for A498 cells). (B) BNIP3 protein levels in 786-O, ACHN, and A498 cells following TSA treatment for 48 h were examined by western blotting. GAPDH was used as an internal control, and cells cultured without TSA were considered as untreated controls (Blank). ^\*^P\<0.05 compared with treatment groups (^a^P\<0.05 compared with the TSA 1.0 *µ*mol/l treatment group). Representative bands are presented under the histograms. TSA, trichostatin A; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.](IJO-54-01-0348-g03){#f4-ijo-54-01-0348}

![Deacetylation status of the *BNIP3* promoter in 786-O, A498 and ACHN cells before and after TSA treatment. Chromatin immunoprecipitation was used to evaluate the deacetylation status of the BNIP3 promoter. The treatment group was treated with 1.0 *µ*mol/l TSA for 48 h. Input DNA was used as a positive control, and extracts were incubated with IgG as a negative control. Ac-H3, polyclonal antibody against acetylated histone H3; -, non-TSA-treatment group; +, TSA-treatment group; TSA, trichostatin A; IgG, immunoglobulin G.](IJO-54-01-0348-g04){#f5-ijo-54-01-0348}

![Mechanistic aspects of the VHL-HIF-BNIP3 signaling pathway. Step A: The binding of HIF-α to VHL and to the E3 ligase complex causes HIF-α to be ubiquitinated and marked for degradation by the cell's proteasomal complex. Step B: In a hypoxic environment, HIF-α cannot bind the VHL protein, and consequently cannot be degraded. Step C: Aberrant functioning of VHL also leads to an accumulation of HIFα. Step D: HIF-α levels rise in the cell, allowing the protein to bind with HIFβ. The HIF-α/β heterocomplex may be translocated to the nucleus and bind to specific HREs. Step E: HREs activates downstream genes, including VEGF, PDGF, TGFα, and several others, which have important roles in tumor growth and progression. BNIP3 can also be activated by HREs. Step F: Structure of the BNIP3 protein: NH2, N-terminal domain; BH3, Bcl-2 homology domain 3; CD, conserved domain; TM, transmembrane domain; CT, COOH-terminal domain; Step G: BNIP3 can induce mitochondrial autophagy in response to environmental changes to promote cell survival. Step H: Under seriously detrimental environmental conditions, excessive mitochondrial autophagy is induced, leading to apoptosis. Step K: BNIP3-induced cell death is also activated under conditions of extreme hypoxia, acidosis and NO. Ub, ubiquitin; HRE, hypoxia-response element; VHL, Hippel-Lindau; HIF-1(α/β), hypoxia-inducible factor-1(α/β); VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor; TGFα, transforming growth factor α.](IJO-54-01-0348-g05){#f6-ijo-54-01-0348}

###### 

Details of the reverse transcription reaction mixtures.

  Reagent           Amount                                                          
  ----------------- ------------------------------- ------------------------------- -------------------------------
  Total RNA         5 *µ*g                          2 *µ*g                          2 *µ*g
  5X RT buffer      4 *µ*l                          4 *µ*l                          4 *µ*l
  dNTPs (10 mM)     2 *µ*l                          2 *µ*l                          2 *µ*l
  DTT (0.1 M)       1 *µ*l                          1 *µ*l                          1 *µ*l
  Oligo (dT) 18     1 *µ*l                          1 *µ*l                          1 *µ*l
  ReverTra Ace^®^   0.8 *µ*l                        1 *µ*l                          1 *µ*l
  DEPC ddH~2~O      Up to total volume of 20 *µ*l   Up to total volume of 20 *µ*l   Up to total volume of 20 *µ*l

The reagents (and their abbreviations) described in the Table were purchased from the following sources, as follows: dNTP (Roche Diagnostics GmbH, Mannheim, Germany); DTT, dithiothreitol (Merck, KGaA, Darmstadt, Germany); ReverTra Ace^®^ (Toyobo Life Science, Osaka, Japan); DEPC, diethyl pyrocarbonate (Sigma Aldrich; now a brand of Merck, KGaA). RCC, renal cell carcinoma; ddH~2~O, doubly distilled H~2~O; TSA, trichostatin A.

###### 

Details of the PCR mixtures for cell lines and methylation-specific PCR.

  A, Cultured cell lines         
  ------------------------------ ---------------
  Reagent                        Amount (*µ*l)
                                 
  *Taq* DNA polymerase           0.25
  10X PCR buffer                 2.5
  25 mmol/l MgCl~2~              1.5
  10 mmol/l dNTP                 0.5
  Upstream primer (100 *µ*M)     0.1
  Downstream primer (100 *µ*M)   0.1
  cDNA                           1
  ddH~2~O                        Up to 25
  B, Methylation-specific PCR    
  Reagent                        Amount (*µ*l)
                                 
  Takara *Taq* HS (5 U/*µ*l)     0.1
  10X HS buffer (Mg^2+^ plus)    2
  2.5 mmol/l dNTP                1.6
  Upstream primer (100 *µ*M)     0.1
  Downstream primer (100 *µ*M)   0.1
  cDNA                           3
  ddH~2~O                        Up to 20

The specific reagents were purchased from the following sources: *Taq* DNA polymerase (Tiangen Biotech Co., Ltd., Beijing, China); Takara *Taq* HS (Takara Biotechnology Co., Ltd., Dalian, China); PCR, polymerase chain reaction; ddH~2~O, doubly distilled H~2~O.

###### 

Details of the reaction mixtures for reverse transcription-quantitative polymerase chain reaction.

  Reagent                           Amount (*µ*l)
  --------------------------------- ---------------
  2X SYBR-Green real-time PCR mix   10
  Upstream primer (10 *µ*M)         0.4
  Downstream primer (10 *µ*M)       0.4
  cDNA                              2.0
  ddH~2~O                           7.2
  Total volume                      20

SYBR-Green real-time PCR mix was purchased from Takara Biotechnology Co., Ltd. (Dalian, China). ddH~2~O, doubly distilled H~2~O.

###### 

PCR reaction details for TSA treated cells and ChIP.

  A, Cells treated with TSA     
  ----------------------------- ---------------
  Reagent                       Amount (*µ*l)
                                
  *Taq* DNA polymerase          0.25
  10X PCR buffer                2.5
  25 mmol/l MgCl~2~             1.5
  10 mmol/l dNTP                0.5
  Upstream primer (10 *µ*M)     0.1
  Downstream primer (10 *µ*M)   0.1
  cDNA                          1
  ddH~2~O                       Up to 25
                                
  B, ChIP                       
                                
  Reagent                       Amount (*µ*l)
                                
  *Taq* DNA polymerase          0.25
  10X PCR buffer                12.5
  25 mmol/l MgCl~2~             \-
  10 mmol/l dNTP                1
  Upstream primer (10 *µ*M)     0.1
  Downstream primer (10 *µ*M)   0.1
  cDNA                          1
  ddH~2~O                       Up to 25

*Taq* DNA polymerase was purchased from Tiangen Biotech Co., Ltd. (Beijing, China). PCR, polymerase chain reaction; ddH~2~O, doubly distilled H~2~O; ChIP, chromatin immunoprecipitation; TSA, trichostatin A.

###### 

Associations between renal cell carcinoma gene expression and clinical data

  Parameter            n    *BNIP3* mRNA                                         *VHL* mRNA   *HIF1A* mRNA   *VEGF* mRNA                                                                                                                                                                                                            
  -------------------- ---- ---------------------------------------------------- ------------ -------------- ----------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------
  Sex                                                                            −0.33                       −0.11                                                                                                       0.01                                                                                                       0.20
   Male                19   0.22                                                              0.46                                                                 13.00                                                                                                      16.50                                                 
   Female              11   0.44                                                              0.51                                                                 10.83                                                                                                      11.52                                                 
  Age (years)               \-                                                   0.03                        −0.21                                                                                                       −0.10                                                                                                      −0.04
   \<65                22   0.30                                                              0.51                                                                 12.37                                                                                                      13.14                                                 
   ≥65                 8    0.28                                                              0.33                                                                 11.03                                                                                                      14.01                                                 
  Diameter of tumor                                                              −0.14                       −0.17                                                                                                       −0.07                                                                                                      0.23
   \<4 cm              7    0.27                                                              0.68                                                                 15.03                                                                                                      16.50                                                 
   ≥4 cm               23   0.34                                                              0.46                                                                 10.82                                                                                                      11.72                                                 
  Clinical stage                                                                 0.21                        0.06                                                                                                        0.84[b](#tfn7-ijo-54-01-0348){ref-type="table-fn"}                                                         −0.37[a](#tfn6-ijo-54-01-0348){ref-type="table-fn"}
   I-II                19   0.22                                                              0.51                                                                 7.52                                                                                                       16.50                                                 
   III-IV              11   0.34                                                              0.51                                                                 39.12                                                                                                      10.90                                                 
  Pathological stage                                                             0.06                        −0.40[a](#tfn6-ijo-54-01-0348){ref-type="table-fn"}                                                         0.47[b](#tfn7-ijo-54-01-0348){ref-type="table-fn"}                                                         −0.09
   I-II                12   0.30                                                              0.57                                                                 6.92                                                                                                       14.11                                                 
   III-IV              18   0.29                                                              0.37                                                                 17.56                                                                                                      13.04                                                 
   Total               30   0.30[a](#tfn6-ijo-54-01-0348){ref-type="table-fn"}                0.51^\*^                                                             12.30[a](#tfn6-ijo-54-01-0348){ref-type="table-fn"}                                                        13.14[a](#tfn6-ijo-54-01-0348){ref-type="table-fn"}   

Expression levels of BNIP3, VHL, HIF1A, and VEGF in tumor and adjacent non-tumor tissue samples from 30 cases of ccRCC were determined by RT-qPCR. Relative expression levels of each gene are shown relative to expression levels in adjacent non-tumor tissue samples, which were set as 1. M, median; r, correlation coefficient; VHL, von Hippel-Lindau; HIF1A, hypoxia-inducible factor-1α; VEGF, vascular endothelial growth factor; ccRCC, clear cell renal cell carcinoma; RT-qPCR, reverse transcription-quantitative polymerase chain reaction. For single-sample non-parametric test and rank correlation,

P\<0.05;

P\<0.01.

[^1]: Contributed equally
